GTC
VKTX icon

Ghost Tree Capital’s Viking Therapeutics VKTX Stock Holding History

Ghost Tree Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-80,000
Closed -$6.56M – 82
2024
Q1 		$6.56M Buy
+80,000
New +$3.56M 1.82% 18

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Ghost Tree Capital's VKTX Position: Q3 2024 in Review

Ghost Tree Capital increased its Viking Therapeutics (VKTX) stake by 47% in Q3 2024, buying an estimated $2.64M and bringing the position to 140,000 shares worth $8.86M. The position accounts for 2.68% of the portfolio, ranked #12.

Ghost Tree Capital first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. The position peaked at $10.5M in Q2 2023. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Ghost Tree Capital held 140,000 shares of Viking Therapeutics worth $8.86M as of Q3 2024.
  • Ghost Tree Capital bought 45,000 Viking Therapeutics shares in Q3 2024, an estimated $2.64M.
  • Viking Therapeutics made up 2.68% of Ghost Tree Capital's portfolio in Q3 2024, its #12 holding.
  • Ghost Tree Capital first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • Ghost Tree Capital's Viking Therapeutics position peaked at $10.5M in Q2 2023.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.